Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Virtual eye model system for personalised refractive surgery treatment

Project description

Presurgical decision support offers benefits that are easy to see

Myopia is the most common ocular disorder. Its global incidence is increasing rapidly, particularly among youth. Around half of the young adults in the US and Europe are short-sighted and the numbers are rising. The underlying defect is a slightly elongated eyeball. In severe cases, it can lead to serious consequences including retinal detachment, cataracts, glaucoma, and even blindness. Refractive surgery (to correct the improper bending of light through the lens) has become a very common and relatively simple treatment. Now, the EU-funded VEMoS project is providing sophisticated pre-surgical support with patented state-of-the-art diagnostics and advanced simulation software to predict post-surgery outcomes. The decision-making tool should enhance outcomes while reducing the risk of complications, helping millions of people worldwide to see more clearly.

Objective

The incidence of myopia is predicted to rise from 28% of the global population in 2010 to almost 50% in 2050. Factors such as population aging and increase of hours spent in front of screens are driving the increase in global eye deficits. Vision impairments reduce the quality of life, affect economic and educational opportunities and increase the risk of death. This is particularly important for vulnerable groups such as elderly, children, workers and drivers. Overall, WHO reported that uncorrected vision was responsible for 241bn of productivity loss per year worldwide.
Our innovative Virtual Eye Model System (VEMoS) is based on patented revolutionary ophthalmic diagnostic devices (CSOs MS-39 tomographer/topographer and the unique open-field aberrometer), as well as on innovative simulation software developed by Vissum. Overall, our innovation provides personalised clinical-decision support based on each patients eye measurements and neural network simulations of post-surgery outcomes, improving surgery success and patient satisfaction rates.
By combining CSOs ophthalmic high-tech hardware design, manufacturing and commercialisation skills with Vissums refractive surgery and software development and independent clinical testing by CHUC and AUH, this project is expected to bring economic, social and health impacts, including progress towards achieving the EC action plan on personalised medicine ICPerMed. Our goal is to mature, scale-up and demonstrate the production of the VEMoS system, targeting ophthalmology clinics as clients, and with the aim to standardise refractive surgery decision making and revolutionise the refractive surgery field with personalised treatments.
A successful VEMoS project will allow us to create measurable impacts on our companies, quantified as accumulated revenue of 145.3m in five years (2022-2026), equal to accumulated operating profit of 58.2m creating 60 full time employments, and generating 37m in reduced customer costs.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

IA - Innovation action

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-FTI-2018-2020

See all projects funded under this call

Coordinator

VALCASADO SA
Net EU contribution
€ 935 852,50
Address
EBANISTAS 4
28923 Alcorcon
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 2 038 455,40

Participants (6)